World Bulletin / News Desk
The U.S. announced Wednesday it had approved a cell-based gene therapy in the United States for the first time.
The “historic action” by the Food and Drug Administration (FDA) permits a new treatment that uses a leukemia patient’s own blood to engineer a method to attack the cancer.
Scientists often refer to this type of gene therapy as a “living drug” because it involves using genetically modified immune cells from patients.
The drug Kymriah was developed by Novartis Pharmaceuticals and the University of Pennsylvania. The treatment was approved for certain children and young adult up to the age of 25 who suffer from a form of acute lymphoblastic leukemia (ALL) -- a cancer of blood and bone marrow that is the most common childhood cancer in the United States.
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” said FDA Commissioner Scott Gottlieb, who was appointed to the position by President Donald Trump earlier this year. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”
Novartis said the treatment has an 83 percent success rate for a form of leukemia that has proven very hard to treat by other methods.
“Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need,” Novartis CEO Joseph Jimenez said in a statement.
The National Cancer Institute estimates 3,100 patients are diagnosed each year with ALL, which can come in several forms. Less than 10 percent of patients with the most common form of ALL survive longer than five years under current treatment regimens, Novartis said.
Equipment donation to children's oncology institute is first project of state-run aid agency TIKA in Brazil
Some 450 other suspected cases seen in island nation; president says health workers are able to contain epidemic
UN says 900,000 doses of oral vaccine are to be given to Rohingya Muslims fleeing violence in neighboring Myanmar
3 cholera quarantine centers have been formed where victims are being treated
12 cases confirmed, 32 persons quarantined to halt spread of disease, says disease control body
Provided by UNICEF, vaccinations will be administered by public health officials in Syria’s Idlib province
Eggs tainted by the insecticide mostly originate from farms in those two countries but have since been found in 45 nations worldwide, the European health commissioner Vytenis Andriukaitisa said last week.
The UN says cholera is a major public health problem in the country with millions of cases registered every year. Last year, the disease claimed 817 lives there, according to the WHO.
The ministerial meeting will include representatives from some 30 countries, according to Canada's minister of environment and climate change, Catherine McKenna.
Cholera is endemic in Nigeria, with a rise in cases during rainy season from April to September, says disease control center
Police officers tested positive for cholera after eating infected food; health minister blames food workers
"Up to September 1, 14 deaths have been reported," the health ministry said in a statement, adding that "the total number of suspected cholera cases stands at 186."
Pharmaceutical company says treatment has more than 80 percent success rate for form of leukemia
Federal agency orders StemImmune to stop injecting vaccine into tumors of cancer patients
565,041 suspected cases of cholera have been recorded in the country since April 27
Unknown health risks include cancer, respiratory diseases, birth defects and reduced cognition